Innovación y propiedad intelectual · 22/5/19961 min de lectura
Notice of Two Year Exclusivity Period; DAYPRORegister Oxaprozin
Traducción automática local · Idioma original de la fuente
Resumen
The Patent and Trademark Office has received notification from G. D. Searle & Co. that it claims entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134) for its drug product DAYPRO oxaprozin.